DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

This approval augments Biocon Pharma's complex injectables portfolio and reinforces its footprint in the US pharma market.

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

ISLAMABAD: The Drug Regulatory Authority Pakistan (DRAP) has issued an immediate recall alert for a number of substandard ...

Top presents for family, friends - Eid Mubarak! The big day is nearly here - time to celebrate with the perfect gift for ...

Gvoke VialDx is a concentrated liquid glucagon product. For diagnostic procedures, it works as a gastrointestinal motility inhibitor. The product is supplied as a single-dose vial containing 1mg of ...

The new formula will replace EGRIFTA SV and treat excess visceral abdominal fat in adults with HIV and Lipodystrophy.

STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...

In downstream processing of biopharmaceutical products, protein aggregation presents one of the main risks in terms of ...

New, improved formulation set to replace EGRIFTA SV®MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or ...

Delhi HC rejects interim injunction plea from Roche against Natco's SMA drug Evrysdi: Our Bureau, New Delhi Thursday, March 27, 2025, 08:00 Hrs [IST] The Delhi High Court has reje ...